TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF THE GLOBAL EXOSOME RESEARCH PRODUCTS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 56
2 MARKET SEGMENTATION 59
2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET APPLICATION COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 75
4.1 PESTEL ANALYSIS 78
4.2 PORTER'S FIVE FORCES MODEL 79
4.3 SUPPLY CHAIN ANALYSIS 80
4.4 VALUE CHAIN ANALYSIS 81
4.5 BUSINESS STRATEGY EXCELLENCE 82
4.6 CASE STUDIES 83
4.7 STRENGTH OF PRODUCT PORTFOLIO 85
4.8 TECHNOLOGICAL TRENDS 87
4.9 PRICING ANALYSIS 88
5 INDUSTRY INSIGHTS 89
6 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, REGULATIONS 90
7 MARKET OVERVIEW 92
7.1 DRIVERS 94
7.1.1 GROWING PREVALENCE OF CANCER, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES 94
7.1.2 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D AND LIFE SCIENCES RESEARCH 94
7.1.3 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES AND PROGRESSING THERAPEUTIC VALUE OF EXOSOME 95
7.2 RESTRAINTS 96
7.2.1 LACK OF GOLD STANDARD PROTOCOLS FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOMES 96
7.2.2 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME 96
7.3 OPPORTUNITIES 97
7.3.1 RISING DEMAND FOR SPECIALIZED TESTING SERVICES AMONG END USERS. 97
7.3.2 INCREASING ADVANCEMENT IN EXOSOME TECHNOLOGY 97
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 98
7.4 CHALLENGES 99
7.4.1 SIDE EFFECTS ASSOCIATED WITH EXOSOME RESEARCH PRODUCTS 99
7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES 99
8 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY PRODUCT 100
8.1 OVERVIEW 101
8.2 CONSUMABLES 104
8.2.1 KITS AND REAGENTS 105
8.2.1.1 EXOSOME BIOMARKER KITS 106
8.2.1.2 EXOSOME ISOLATION KITS 106
8.2.1.3 EXOSOME PURIFICATION KITS 106
8.2.1.4 EXOSOME QUANTITATIVE KITS 106
8.2.1.5 EXOSOME DETECTION KITS 106
8.2.1.6 OTHERS 106
8.2.2 EXOSOME STANDARDS 106
8.2.3 EXOSOME ANTIBODIES 106
8.2.4 CELL LINES 106
8.2.5 IMMUNOPLATES 107
8.2.6 IMMUNOBEADS 107
8.2.7 BIOFLUIDS 107
8.2.8 OTHERS 107
8.3 INSTRUMENTS 107
8.3.1 BENCHTOP 108
8.3.2 STANDALONE 108
9 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY INDICATION 109
9.1 OVERVIEW 110
9.2 CANCER 113
9.2.1 LUNG CANCER 114
9.2.2 BREAST CANCER 114
9.2.3 COLORECTAL CANCER 114
9.2.4 PROSTATE CANCER 115
9.2.5 OTHER CANCER 115
9.3 NON-CANCER 115
9.3.1 CARDIOVASCULAR DISEASE 116
9.3.2 NEURODEGENERATIVE DISEASE 116
9.3.3 INFECTIOUS DISEASE 116
9.3.4 OTHERS 116
10 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET: BY APPLICATION 117
10.1 OVERVIEW 118
10.2 THERAPEUTICS 121
10.3 CONSUMABLES 122
10.4 INSTRUMENTS 122
10.5 DIAGNOSIS 122
10.6 CONSUMABLES 123
10.7 INSTRUMENTS 123
11 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY END USER 124
11.1 OVERVIEW 125
11.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANY 128
11.3 CONSUMABLES 129
11.4 INSTRUMENTS 129
11.5 RESEARCH CENTRES 129
11.6 CONSUMABLES 130
11.7 INSTRUMENTS 130
11.8 ACADEMIC INSTITUTES 130
11.9 CONSUMABLES 131
11.10 INSTRUMENTS 131
11.11 CLINICAL TESTING LABORATORY 131
11.12 CONSUMABLES 132
11.13 INSTRUMENTS 132
11.14 HOSPITALS 133
11.15 CONSUMABLES 134
11.16 INSTRUMENTS 134
11.17 OTHERS 134
12 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 135
12.1 OVERVIEW 136
12.2 THIRD PARTY DISTRIBUTORS 139
12.3 DIRECT SALES 139
12.4 ONLINE 140
13 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, BY REGION 141
13.1 OVERVIEW 142
13.2 NORTH AMERICA 147
13.2.1 U.S. 157
13.2.2 CANADA 163
13.2.3 MEXICO 169
13.3 EUROPE 175
13.3.1 GERMANY 186
13.3.2 U.K. 192
13.3.3 FRANCE 198
13.3.4 ITALY 204
13.3.5 SPAIN 210
13.3.6 RUSSIA 216
13.3.7 SWITZERLAND 222
13.3.8 NETHERLANDS 228
13.3.9 TURKEY 234
13.3.10 SWEDEN 240
13.3.11 POLAND 246
13.3.12 NORWAY 252
13.3.13 BELGIUM 258
13.3.14 FINLAND 264
13.3.15 DENMARK 270
13.3.16 REST OF EUROPE 276
13.4 ASIA-PACIFIC 277
13.4.1 CHINA 287
13.4.2 JAPAN 293
13.4.3 INDIA 299
13.4.4 SOUTH KOREA 305
13.4.5 AUSTRALIA 311
13.4.6 SINGAPORE 317
13.4.7 MALAYSIA 323
13.4.8 THAILAND 329
13.4.9 INDONESIA 335
13.4.10 PHILIPPINES 341
13.4.11 NEW ZEALAND 347
13.4.12 VIETNAM 353
13.4.13 TAIWAN 359
13.4.14 REST OF ASIA-PACIFIC 365
13.5 SOUTH AMERICA 366
13.5.1 BRAZIL 376
13.5.2 ARGENTINA 382
13.5.3 REST OF SOUTH AMERICA 388
13.6 MIDDLE EAST AND AFRICA 389
13.6.1 SOUTH AFRICA 399
13.6.2 EGYPT 405
13.6.3 SAUDI ARABIA 411
13.6.4 U.A.E 417
13.6.5 BAHARAIN 422
13.6.6 KUWAIT 428
13.6.7 OMAN 434
13.6.8 QATAR 440
13.6.9 MIDDLE EAST AND AFRICA 446
14 GLOBAL EXOSOME RESEARCH PRODUCTS MARKET, COMPANY LANDSCAPE 447
14.1 COMPANY SHARE ANALYSIS: GLOBAL 447
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 448
14.3 COMPANY SHARE ANALYSIS: EUROPE 449
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 450
15 SWOT ANALYSIS 451
16 COMPANY PROFILE 452
16.1 THERMO FISHER SCIENTIFIC INC. 452
16.1.1 COMPANY SNAPSHOT 452
16.1.2 REVENUE ANALYSIS 452
16.1.3 COMPANY SHARE ANALYSIS 453
16.1.4 PRODUCT PORTFOLIO 453
16.1.5 RECENT DEVELOPMENT 454
16.2 EXODX (ACQUIRED BY BIO-TECHNE) 455
16.2.1 COMPANY SNAPSHOT 455
16.2.2 REVENUE ANALYSIS 455
16.2.3 COMPANY SHARE ANALYSIS 456
16.2.4 PRODUCT PORTFOLIO 456
16.2.5 RECENT DEVELOPMENT 456
16.3 MILTENYI BIOTEC 457
16.3.1 COMPANY SNAPSHOT 457
16.3.2 COMPANY SHARE ANALYSIS 457
16.3.3 PRODUCT PORTFOLIO 458
16.3.4 RECENT DEVELOPMENTS 458
16.4 LUMINEX CORPORATION 459
16.4.1 COMPANY SNAPSHOT 459
16.4.2 PRODUCT PORTFOLIO 459
16.4.3 RECENT DEVELOPMENT 459
16.5 HOLOGIC, INC. 460
16.5.1 COMPANY SNAPSHOT 460
16.5.2 REVENUE ANALYSIS 460
16.5.3 COMPANY SHARE ANALYSIS 461
16.5.4 PRODUCT PORTFOLIO 461
16.5.5 RECENT DEVELOPMENTS 461
16.6 AETHLON MEDICAL, INC. (2022) 462
16.6.1 COMPANY SNAPSHOT 462
16.6.2 PRODUCT PORTFOLIO 463
16.6.3 RECENT DEVELOPMENTS 463
16.7 AGILENT TECHNOLOGIES, INC. 464
16.7.1 COMPANY SNAPSHOT 464
16.7.2 REVENUE ANALYSIS 464
16.7.3 PRODUCT PORTFOLIO 465
16.7.4 RECENT DEVELOPMENT 465
16.8 AMSBI0 466
16.8.1 COMPANY SNAPSHOT 466
16.8.2 PRODUCT PORTFOLIO 466
16.8.3 RECENT DEVELOPMENT 466
16.9 AUDUBON BIOSCIENCE. 467
16.9.1 COMPANY SNAPSHOT 467
16.9.2 PRODUCT PORTFOLIO 467
16.9.3 RECENT DEVELOPMENT 467
16.10 BECKMAN COULTER, INC 468
16.10.1 COMPANY SNAPSHOT 468
16.10.2 PRODUCT PORTFOLIO 468
16.10.3 RECENT DEVELOPMENT 468
16.11 BIOVISION INC. (ACQUIRED BY ABCAM PLC) 469
16.11.1 COMPANY SNAPSHOT 469
16.11.2 REVENUE ANALYSIS 469
16.11.3 COMPANY SHARE ANALYSIS 470
16.11.4 PRODUCT PORTFOLIO 470
16.11.5 RECENT DEVELOPMENT 470
16.12 CELL GUIDANCE SYSTEMS LLC 471
16.12.1 COMPANY SNAPSHOT 471
16.12.2 PRODUCT PORTFOLIO 471
16.12.3 RECENT DEVELOPMENTS 471
16.13 CREATIVE BIOARRAY 472
16.13.1 COMPANY SNAPSHOT 472
16.13.2 PRODUCT PORTFOLIO 472
16.13.3 RECENT DEVELOPMENT 472
16.14 CUSABIO TECHNOLOGY LLC 473
16.14.1 COMPANY SNAPSHOT 473
16.14.2 PRODUCT PORTFOLIO 473
16.14.3 RECENT DEVELOPMENTS 473
16.15 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION 474
16.15.1 COMPANY SNAPSHOT 474
16.15.2 REVENUE ANALYSIS 474
16.15.3 PRODUCT PORTFOLIO 475
16.15.4 RECENT DEVELOPMENT 475
16.16 HBMLS (ACQUIRED BY LONZA) 476
16.16.1 COMPANY SNAPSHOT 476
16.16.2 REVENUE ANALYSIS 476
16.16.3 PRODUCT PORTFOLIO 477
16.16.4 RECENT DEVELOPMENT 477
16.17 HITACHI, LTD. 478
16.17.1 COMPANY SNAPSHOT 478
16.17.2 REVENUE ANALYSIS 478
16.17.3 PRODUCT PORTFOLIO 479
16.17.4 RECENT DEVELOPMENT 479

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.